Trial-Results center  
Clinical trial results database in 100 Feedback    Home


Related trials

Buse, 2011 - exenatide vs placebo add on insulin

Lewin, 2010 - linagliptin vs placebo (add on to sulphonylurea)

DURATION-2 (Bergenstal) (vs sitagliptin), 2010 - exenatide vs sitagliptin

DURATION-3 (Diamant), 2010 - exenatide vs insulin glargine

Ratner DRI6012, 2010 - lixisenatide vs placebo add on MET

DURATION-2 (Bergenstal) (vs pioglitazone), 2010 - exenatide vs pioglitazone

Goodman, 2009 - vildagliptin vs placebo (add on to metformin)

HOME, 2009 - metformin vs placebo

LEAD-2 (Nauck) (vs placebo), 2009 - liraglutide vs placebo add on MET

Nauck (Sulf vs pbo), 2009 - vs placebo

9607, 2009 - exenatide vs placebo add on MET+/-SU

Li, 2009 - nateglinide vs repaglinide

LEAD-2 (vs MET), 2009 - liraglutide vs metformin

Ferrannini, 2009 - vildagliptin vs Sulfonylurea (add on to metformin)

LEAD-3 mono (Garber), 2009 - liraglutide vs glimepiride

Kaku, 2009 - mitiglinide vs placebo (on top pioglitazone )

COSMIC, 2009 - vs

LEAD-2 (Nauck) (vs glimepiride), 2009 - liraglutide vs glimepiride add on MET

DeFronzo, 2009 - saxagliptin vs placebo (add on to metformin)

RECORD, 2009 - rosiglitazone vs standard glucose-lowering drugs

Nauck, 2009 - alogliptin vs placebo (add on to metformin)

Nauck (vs GLP-1 analog), 2009 - vs GLP-1 analog

Filozof, 2009 - vildagliptin as add-on therapy vs gliclazide

Bolli, 2008 - vildagliptin vs pioglitazone (on top of metformin)

Moretto, 2008 - exenatide vs placebo



See also:

  • All test diab�te clinical trials
  • All diabetes clinical trials
  • All type 2 diabetes - sanofi clinical trials
  • All clinical trials of insulin secretagogues peptides (incretins)
  • All clinical trials of liraglutide
    		•  

    Vilsboll study, 2008

    download pdf: liraglutide | insulin secretagogues peptides (incretins) for diabetes

    Treatments

    Studied treatment Liraglutide 0.65�1.90 mg daily
    Control treatment Placebo
    Concomittant treatment None

    Patients

    Patients patients with Type 2 diabetes
    Baseline characteristics
    Age (year) 55  
    Duration of diabetes (year) 5.0 y 
    HbA1c (%) 8.3 
    BMI 30.0 
    Add-on to None 

    Method and design

    Randomized effectives 123 / 40 (studied vs. control)
    Design parallel groups
    Blinding double blind (not adequate)
    Follow-up duration 14 weeks


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    severe hypoglycemia

    0 / 123
         0 / 40
         classic 0,33 [0,00;82,18]

    vomiting

    4 / 123
         0 / 40
         classic 5,53 [0,10;307,28]

    cardiovascular events

    0 / 123
         0 / 40
         classic 0,33 [0,00;82,18]

    all hypoglycemia

    0 / 123
         0 / 40
         classic 0,33 [0,00;82,18]

    nausea

    9 / 123
         1 / 40
         classic 2,93 [0,38;22,40]

    diarrhoea

    26 / 123
         5 / 40
         classic 1,69 [0,70;4,11]

    All cause death

    0 / 123
         0 / 40
         classic 0,33 [0,00;82,18]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    severe hypoglycemia 0 / 123 (0,4%) 0 / 40 (1,3%) 0,33 [0,01;16,13] 12053
    vomiting 4 / 123 (3,3%) 0 / 40 (1,3%) 2,60 [0,14;48,15] 12053
    cardiovascular events 0 / 123 (0,4%) 0 / 40 (1,3%) 0,33 [0,01;16,13] 12053
    all hypoglycemia 0 / 123 (0,4%) 0 / 40 (1,3%) 0,33 [0,01;16,13] 12053
    nausea 9 / 123 (7,3%) 1 / 40 (2,5%) 2,93 [0,38;22,40] 0
    diarrhoea 26 / 123 (21,1%) 5 / 40 (12,5%) 1,69 [0,70;4,11] 12053
    All cause death 0 / 123 (0,4%) 0 / 40 (1,3%) 0,33 [0,01;16,13] 12053
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 12053: Monami M, Marchionni N, Mannucci EGlucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.Eur J Endocrinol 2009;160:909-17
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    nausea 7,32% 2,50% 4,8%
    diarrhoea 21,14% 12,50% 8,6%

    Meta-analysis of all similar trials:

    antidiabetic drugs in test diab�te for type 2 daibetes (NIDD)

    insulin secretagogues peptides (incretins) in diabetes for all type of patients

    insulin secretagogues peptides (incretins) in type 2 diabetes - sanofi for all type of patients



    Reference(s)

    Trials register # NA
    • Vilsb�ll T, Brock B, Perrild H, Levin K, Lervang HH, K�lendorf K, Krarup T, Schmitz O, Zdravkovic M, Le-Thi T, Madsbad S. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.. Diabet Med 2008;25:152-6 - 10.1111/j.1464-5491.2007.02333.x
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend